Want to see NVCT full AI Analyst Report?

Nuvectis Pharma (NVCT) Price & Analysis

124 Followers

NVCT Stock Chart & Stats

$8.90

-$0.26(-4.17%)

At close: Jan 08 4:00 PM EST

$8.90

-$0.26(-4.17%)

Day’s Range― - ―

52-Week Range$5.55 - $29.28

Previous CloseN/A

Volume31.37K

Average Volume (3M)89.48K

Market Cap

$616.95M

Enterprise Value$308.83M

Total Cash (Recent Filing)$25.13M

Total Debt (Recent Filing)$0.00

Price to Earnings (P/E)―

Beta1.46

Next Earnings

Aug 11, 2026

EPS Estimate

-0.26

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.31

Shares Outstanding31,525,534

10 Day Avg. Volume112,705

30 Day Avg. Volume89,483

Financial Highlights & Ratios

PEG Ratio-0.30

Price to Book (P/B)8.94

Price to Sales (P/S)0.00

P/FCF Ratio-10.29

Enterprise Value/Market Cap0.50

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/Ebitda-11.01

Forecast

1Y Price Target

$27.75

Price Target Upside211.80% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering4

EPS Forecast (FY)-1.05

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Debt-free Balance SheetZero total debt and positive shareholders' equity (~$14.2M TTM) provide durable financial flexibility for a clinical-stage biotech. Low leverage reduces bankruptcy and interest-service risk, making future fundraising less constrained by debt covenants and supporting continued R&D investment over months.

Portfolio Expansion Via Haisco LicenseAcquiring global rights to NXP100 (Factor B inhibitor) and NXP200 (brain-penetrant BRAF inhibitor) materially broadens the pipeline across rare complement diseases and oncology. The deal adds high-value clinical assets and strategic optionality to pursue markets with multi-billion dollar potential, strengthening long-term growth prospects.

Material Equity Financing To Support DevelopmentA firm-commitment offering expected to generate roughly $93M (or ~$107M with the option) meaningfully extends the company's runway, enabling continued clinical development of lead programs, hiring, and operating costs. This reduces near-term funding pressure and supports planned R&D execution over multiple quarters.

Bears Say

Pre-revenue With Widening LossesNuvectis remains pre-revenue with materially higher TTM losses versus the prior year, meaning continued reliance on financing to sustain operations. Persistently negative operating results increase cumulative funding needs and extend the path to self-sustaining cash generation absent successful product approvals or partnering outcomes.

Dilution And Recurring Financing RiskFrequent equity raises and the recent large offering relieve cash strain but dilute existing shareholders and signal recurring capital dependence. For a pre-commercial biotech, ongoing dilution risk can erode per-share economics and requires successful program milestones to justify cumulative issuance over time.

Substantial Milestone/royalty Obligations & Financing ConditionsThe Haisco deal embeds large contingent payments and royalties that will materially reduce net economics if programs succeed, while financing conditions before effectiveness create execution risk. These obligations can strain future cash flows or require further funding, altering long-term returns to shareholders.

Nuvectis Pharma News

Midday Fly By: Patrick to combine with LCI, AeroVironment reports Q4 beat

The major averages were broadly higher near noon to close out the second quarter as traders continue to...

5d ago

Nuvectis Pharma 5M share Spot Secondary priced at $20.00

The deal range was $20.00-$22.00. Cantor Fitzgerald acted as sole book running manager for the offering. Published first...

6d ago

NVCT

Closing Bell Movers: AeroVironment jumps after quarterly report

Stock futures were fractionally lower following Monday’s regular session gains as investors await news out of the Middle...

6d ago

AVAV

Nuvectis Pharma TBA Spot Secondary; price range $20.00-$22.00

Cantor Fitzgerald is acting as sole book running manager for the offering. Published first on TheFly – the...

6d ago

NVCT

Nuvectis Pharma announces common stock offering, no amount given

Nuvectis Pharma (NVCT) announced that it has commenced an underwritten public offering of its common stock. All of...

6d ago

NVCT

Nuvectis Pharma price target raised to $22 from $18 at Lucid Capital

Lucid Capital analyst Christopher Liu raised the firm’s price target on Nuvectis Pharma (NVCT) to $22 from $18...

13d ago

NVCT

Nuvectis Pharma price target raised to $39 from $13 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nuvectis Pharma (NVCT) to $39 from $13 and keeps a...

13d ago

NVCT

Nuvectis Pharma announces license agreement with Haisco for two compounds

Nuvectis Pharma (NVCT) announced a strategic portfolio expansion via a license agreement for exclusive ex-China rights with Haisco...

13d ago

NVCT

Nuvectis Pharma price target raised to $13 from $10 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Nuvectis Pharma (NVCT) to $13 from $10 and keeps a...

23d ago

NVCT

Nuvectis Pharma Announces Major Public Equity Offering

Nuvectis Pharma ( ($NVCT) ) has shared an announcement. On June 29, 2026, Nuvectis Pharma entered into an...

5d ago

NVCT

Nuvectis Pharma Suspends Equity Offering Program Under Agreement

Nuvectis Pharma ( ($NVCT) ) has issued an announcement. On May 9, 2025, Nuvectis Pharma, Inc. entered into...

6d ago

NVCT

Nuvectis Pharma Expands Portfolio with Haisco License Deal

An announcement from Nuvectis Pharma ( ($NVCT) ) is now available. On June 22, 2026, Nuvectis Pharma signed...

12d ago

NVCT

Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets

WSW, NY, June 22nd, 2026, FinanceWire Nuvectis Pharma (NASDAQ:NVCT) opened the trading week with a transaction that transforms...

13d ago

ALMS

NVCT

Nuvectis Shareholders Approve Director Election and Auditor Ratification

Nuvectis Pharma ( ($NVCT) ) has shared an announcement. On June 11, 2026, Nuvectis Pharma, Inc. held its...

23d ago

NVCT

NVCT FAQ

What was Nuvectis Pharma’s price range in the past 12 months?

Nuvectis Pharma lowest stock price was $5.55 and its highest was $29.27 in the past 12 months.

What is Nuvectis Pharma’s market cap?

Nuvectis Pharma’s market cap is $616.95M.

When is Nuvectis Pharma’s upcoming earnings report date?

Nuvectis Pharma’s upcoming earnings report date is Aug 11, 2026 which is in 37 days.

How were Nuvectis Pharma’s earnings last quarter?

Nuvectis Pharma released its earnings results on May 05, 2026. The company reported -$0.26 earnings per share for the quarter, beating the consensus estimate of -$0.314 by $0.054.

Is Nuvectis Pharma overvalued?

According to Wall Street analysts Nuvectis Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Nuvectis Pharma pay dividends?

Nuvectis Pharma does not currently pay dividends.

What is Nuvectis Pharma’s EPS estimate?

Nuvectis Pharma’s EPS estimate is -0.26.

How many shares outstanding does Nuvectis Pharma have?

Nuvectis Pharma has 31,525,534 shares outstanding.

What happened to Nuvectis Pharma’s price movement after its last earnings report?

Nuvectis Pharma reported an EPS of -$0.26 in its last earnings report, beating expectations of -$0.314. Following the earnings report the stock price went up 9.224%.

Which hedge fund is a major shareholder of Nuvectis Pharma?

Currently, no hedge funds are holding shares in NVCT

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Nuvectis Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-147.78%

Trailing 12-Months

Asset Growth

-15.76%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Nuvectis Pharma

Nuvectis Pharma, Inc. operates as a biopharmaceutical firm specializing in the development of targeted therapies to address critical, unmet needs within the field of oncology. The company's innovative pipeline features NXP800, a novel compound engineered to inhibit the heat shock factor 1 pathway for treating various forms of cancer. Another promising asset is NXP900, a small molecule drug candidate crafted to suppress the Proto-oncogene c-Src and YES1 kinases. This Fort Lee, New Jersey-based organization was established in 2020.

Nuvectis Pharma (NVCT) Earnings & Revenues

Historic Earnings Reports

NVCT Stock 12 Month Forecast

Average Price Target

$27.75

▲(211.80% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"4":"$4","13":"$13","22":"$22","31":"$31","40":"$40"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":39,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$39.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.75,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.75</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[4,13,22,31,40],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Oct<br/>2025","6":"Jan<br/>2026","9":"Apr<br/>2026","12":"Jul<br/>2026","25":"Jul<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.52,21.018461538461537,22.516923076923078,24.015384615384615,25.513846153846153,27.012307692307694,28.51076923076923,30.00923076923077,31.50769230769231,33.00615384615385,34.504615384615384,36.00307692307692,37.50153846153846,{"y":39,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.52,20.153076923076924,20.786153846153844,21.41923076923077,22.052307692307693,22.685384615384613,23.318461538461538,23.951538461538462,24.584615384615383,25.217692307692307,25.85076923076923,26.48384615384615,27.116923076923076,{"y":27.75,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,19.52,19.556923076923077,19.593846153846155,19.630769230769232,19.667692307692306,19.704615384615384,19.74153846153846,19.77846153846154,19.815384615384616,19.852307692307694,19.889230769230767,19.926153846153845,19.963076923076922,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.31,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.8,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.38,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.06,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.71,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.94,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.55,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.36,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.04,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.6,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.54,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.75,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.52,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >